5 WE HEAR & SAY NPWEB0492014 Date of Prepara on: September 2014

in rst HEALTHCARE secures rights to market Granulox, a novel treatment for accelerated healing of chronic wounds

December 18 2013

infirst HEALTHCARE has secured exclusive rights to market Granulox in the UK, US and all English-speaking countries. Granulox is a patented treatment proven to significantly shorten healing me for chronic wounds.

Chronic wound is a high unmet-need condi on. The primary risk groups are1 those over 80 years old with an annual incidence to develop venous ulcers of 20 per 1000, hospital in-pa with a risk to develop pressure ulcers of 40 per 1000 and diabe p with a life me risk of developing foot ulcers as high as 25%.Annually chronic wounds lead to around 6,000 diabetes-related amputa ons2 and contribute to con nued high levels of MRSA infec ons, implicated in more than 5,000 deaths3. The cost to the NHS directly linked to chronic wound care is es mated to be approximately £1 Billion annually4, with signs of significant growth as the pa ent popula on con nues to age.

Lack of oxygen (hypoxia) is the core issue in impaired wound healing. Poorly healing wounds need oxygen just as much as one needs oxygen for breathing. Granulox is a haemoglobin spray, which addresses this challenge. Once applied it immediately starts to transport oxygen from the surrounding air down to the wound bed.

Granulox has shown to contribute significantly to wound size reduc on and wound healing. In a study with 72 pa ents suffering from venous leg ulcers, half received standard wound care while half were treated with Granulox spray in add on to standard care. A er 13 weeks the ‘Granulox group’ showed an average wound size reduc on of 53 per cent and the ‘standard care group’ presented no sta cally significant improvement in wound size. 5)

Manfred Scheske, infirst HEALTHCARE’s CEO commented: “It is infirst HEALTHCARE’s mission to find, develop and offer early interven on treatment op ons for unmet and poorly met healthcare needs. Granulox is a perfect fit with our strategic agenda and we are convinced this product will contribute to reduce suffering of ents, improve public health and lower the associated healthcare costs.”

Granulox, is owned by Sastomed of Germany, which owns global IP and holds a Europe-wide medical device license (CE mark) for the product.

Ends

For all media enquiries, please contact:

Kelly Blaney – Good Rel ons Brand Communica ons E: KBlaney@goodrela ons.co.uk / t: 020 7861 3140

5 WE HEAR & SAY NPWEB0492014 Date of Prepara on: September 2014

About in rst healthcare: infirst HEALTHCARE is a UK-based healthcare company which spun out of the SEEK drug discovery group in early 2013. Its developments aim to build on the trust and safety of well-known drugs and to develop formu ons which result in a genuinely perceived difference in performance. The u mate goal is improved and highly effec ve health management at an early interv on stage, involving , the family p oners and paediatricians as well as pharmacists.

Among infirst HEALTHCARE’s shareholders is Invesco Perpetual, one of the UK’s largest independent investment funds. Infirst HEALTHCARE is run by Manfred Scheske, an ex-GSK veteran who led GSK’s North American and European Consumer Healthcare businesses for a combined 12 years.

About SastoMed: SastoMed is a German Biotech Joint Venture which has specialized in novel treatments of chronic wounds. SastoMed is jointly owned by Sangui BioTec and SanderStrothmann. SastoMed holds the global rights to commercialise IP related to the use of haemoglobin for treatment of inadequate oxygena on of ue.

About Chronic Wounds: Chronic wounds do not heal in an orderly set of stages and in a predictable amount of me (within 3 months), the way most wounds do6). The most common reasons and or underlying condi ons are diabetes (foot), poor blood circu on (venous leg ulcers) and constant pressure (pressure ulcers/ bed soreness). Poor blood supply and inadequate sue oxygena on contribute to bacterial coloniz on. There is increasing evidence that bacteria within chronic wounds develop resistance to an bio c treatment7. In add on, pa ents that carry drug-resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA) have more chronic wounds5.

References:

1) h p://www.kirklees.nhs.uk/fileadmin/documents/your_health/Infec on_preven on_and_control/Care_homes/High_Impact_Interven on.pdf

2) h p://www.diabetes.org.uk/Documents/Reports/pu ng-feet-first-foot-a ack-report022013.pdf

3) h p://www.nhs.uk/condi ons/mrsa/documents/rcn%20mrsa%20guidelines.pdf

4) h p://www.ntac.nhs.uk/web/FILES/A098_Promogran_briefing_pack_final.pdf

5) h p://granulox.de/wp-content/uploads/2013/10/Studie-Der-Hautarzt-2013-engl.pdf

6) h p://www.ncbi.nlm.nih.gov/pmc/ar cles/PMC3732600/

7) h p://www.ncbi.nlm.nih.gov/pubmed/15021046

Disclaimer:You are now leaving www.infirst.co.uk. Links to all outside websites are provided as a resource to our visitors. infirst accepts no responsibility for the content of other websites.